Cytokinetics, Incorporated
Polaris added Cytokinetics following FDA approval of Myqorzo for hypertrophic cardiomyopathy. The fund believes Myqorzo compares favorably with Bristol Myers Squibb's Camzyos…
CYTK
2 published ideas on Cytokinetics, Incorporated across 2 funds — 2 long and 0 short.
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on Cytokinetics, Incorporated: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Polaris added Cytokinetics following FDA approval of Myqorzo for hypertrophic cardiomyopathy. The fund believes Myqorzo compares favorably with Bristol Myers Squibb's Camzyos…
Polaris added Cytokinetics after FDA approval of Myqorzo for hypertrophic cardiomyopathy. The manager views Myqorzo as superior to Bristol Myers Squibb's Camzyos because it…